Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/11/2007 First Published: 3/1/2001


1.		Phase III Randomized Study of Sequential High-Dose Ifosfamide, Carboplatin, and Etoposide Phosphate Followed By Autologous Peripheral Blood Stem Cell or Bone Marrow Transplantation Versus Standard Ifosfamide, Carboplatin, and Etoposide in Patients With Limited or Extensive Stage Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				65 and under				Other				EBMT-RANDOM-ICE EU-98001, NCI-V01-1645, NCT00011921

Last Modified: 12/11/2006 First Published: 1/25/2006


2.		Phase III Study of Neoadjuvant Chemotherapy in Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Blood Stem Cell Support

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Under 1				Other				CCLG-NB-1999-03 EU-20597, NCT00417053

Last Modified: 7/31/2008 First Published: 2/10/2006


3.		Phase III Study of Combination Chemotherapy Comprising Carboplatin or Cisplatin, Etoposide Phosphate, and Ifosfamide and Radiotherapy in Patients With Intracranial Germ Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				CCLG-GC-1997-01 EU-20579, SIOP-CNS-GCT-96, NCT00293358

Last Modified: 1/9/2009 First Published: 3/3/2006


4.		Phase III Study of Doxorubicin Hydrochloride, Vincristine, Prednisone, and Cyclophosphamide Followed by Response-Directed Radiotherapy in Children and Adolescents With Newly Diagnosed Low-Risk Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				21 and under				NCI				COG-AHOD0431 AHOD0431, NCT00302003

Last Modified: 12/18/2002 First Published: 10/1/1997


5.		Phase I/II Study of Topotecan as a Component of Multicourse High Dose Chemotherapy with Peripheral Blood Stem Cell Support in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				CPMC-IRB-7866 NCI-G97-1327, NCT00003064

Last Modified: 5/1/2002 First Published: 6/1/2000


6.		Phase I/II Study of Intensive Dose Melphalan, Topotecan, and Etoposide Phosphate Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma (Summary Last Modified 05/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				15 to 69				NCI				MCC-11752 MCC-IRB-4983, NCI-G00-1749, NCT00005792

Last Modified: 10/6/2008 First Published: 6/1/2001


7.		Phase II Pilot Study of Intensification Comprising High-Dose Thiotepa and Cyclophosphamide With Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) and Sargramostim (GM-CSF) Followed By High-dose Carboplatin, Etoposide, and Melphalan With Second PBSCT, GM-CSF, and Isotretinoin After Induction Therapy in Children With Newly Diagnosed High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				30 and under at original diagnosis				NCI				COG-ANBL00P1 NCT00017368

Last Modified: 5/7/2008 First Published: 11/20/2003


8.		Phase II Study of Rituximab, Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption and High-Dose Sodium Thiosulfate and Cytarabine in Patients With Refractory or Recurrent Primary CNS Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Temporarily closed				18 months to 75 years				NCI				OHSU-7465 OHSU-641, OHSU-ONC-02059-LX, NCT00074165

Last Modified: 1/19/2007 First Published: 11/20/2003


9.		Phase II Study of Methotrexate, Cyclophosphamide, and Etoposide Phosphate Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption and Dexamethasone and Cytarabine in Patients With Primary CNS Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				16 to 75				NCI				OHSU-5729-2 OHSU-ONC-99055-L, CASE-CCF-3669, NCT00074178


10.		Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and under				Other				CNS 0294 NCT00179920

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute